FATE

Fate Therapeutics, Inc.

2.25 USD

Last updated Dec 11, 08:56 UTC

Yesterday HIGH

$2.4

Yesterday LOW

$2.24

52w HIGH

$21.1

52w LOW

$1.63

EPS

-0.46

PE

-4.89

Next Earnings

Feb 27, 2024

Overview News Insider Transactions Government Trades

Fate Therapeutics, Inc. stock is up 9.22% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54.55% of the previous 10 December’s closed higher than November. 50% of analysts rate it a buy.

Fate Therapeutics, Inc. develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cells product candidates.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

San Diego, United States Of America

Website

fatetherapeutics.com

Benzinga Insights

Mon Aug 14, 2023

Stocks That Hit 52-Week Lows On Monday

During Monday's session, 201 stocks hit new 52-week lows.
Benzinga Insights

Fri Aug 11, 2023

Stocks That Hit 52-Week Lows On Friday

During the Friday's sesion, 157 stocks hit new 52-week lows.
Benzinga Insights

Thu Aug 10, 2023

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 128 companies set new 52-week lows.
Benzinga Newsdesk

Thu Aug 10, 2023

Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $5

Morgan Stanley analyst Michael Ulz maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $8 to $5.
Benzinga Newsdesk

Thu Aug 10, 2023

Barclays Maintains Overweight on Fate Therapeutics, Lowers Price Target to $6

Barclays analyst Peter Lawson maintains Fate Therapeutics (NASDAQ:FATE) with a Overweight and lowers the price target from $12 to $6.
richadhand@benzinga.com

Wed Aug 9, 2023

BMO Capital Maintains Market Perform on Fate Therapeutics, Lowers Price Target to $5.4

BMO Capital analyst Etzer Darout maintains Fate Therapeutics (NASDAQ:FATE) with a Market Perform and lowers the price target from $6 to $5.4.
richadhand@benzinga.com

Wed Aug 9, 2023

EF Hutton Reiterates Buy on Fate Therapeutics, Maintains $10 Price Target

EF Hutton analyst Tony Butler reiterates Fate Therapeutics (NASDAQ:FATE) with a Buy and maintains $10 price target.
mahesh@benzinga.com

Tue Aug 8, 2023

Fate Therapeutics Q2 EPS $(0.54) Beats $(0.59) Estimate, Sales $933.00K Miss $5.53M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.59) by 8.47 percent. This is a 31.65 percent increase over losses of $(0.79) per share from
Benzinga Insights

Tue Aug 8, 2023

Earnings Scheduled For August 8, 2023

Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share on revenue of $1.48 billion.
Benzinga Insights

Mon Aug 7, 2023

Stocks That Hit 52-Week Lows On Monday

On Monday, 149 companies reached new 52-week lows.

Mizuho

Mon Nov 20, 10:47

buy

confirm
Morgan Stanley

Mon Nov 13, 09:08

hold

confirm